Propanc Biopharma公司PRP药物I B期首次人体试验定于2026年启动;1亿美元资金设施已就位

美股速递
Mar 12

生物制药公司Propanc Biopharma Inc宣布,其主打候选药物PRP的I B期首次人体临床试验计划于2026年正式开展。该公司已确保一项高达1亿美元的资金支持,为临床试验的顺利推进提供了坚实的财务保障。

此次I B期试验标志着PRP在研发进程中迈出关键一步,旨在评估该药物在人体中的安全性与初步疗效。充足的资金储备将助力公司高效执行临床开发计划,加速潜在疗法的上市进程。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10